Drug Type Small molecule drug |
Synonyms MAVA, MAVA-Myokardia, HCM 1 + [6] |
Target |
Mechanism Cardiac myosin inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (28 Apr 2022), |
RegulationPriority Review (CN), Breakthrough Therapy (CN), Orphan Drug (KR), Breakthrough Therapy (US), Orphan Drug (US) |
Molecular FormulaC15H19N3O2 |
InChIKeyRLCLASQCAPXVLM-NSHDSACASA-N |
CAS Registry1642288-47-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertrophic obstructive cardiomyopathy | US | 28 Apr 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | US | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | CN | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | JP | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | AU | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | AT | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | BE | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | BR | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | CA | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | CZ | 14 Dec 2022 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | DK | 14 Dec 2022 |
Phase 3 | 38 | iqiltypfgp(oygdnsaukt) = olfjfmuhgi dbuofltbez (xvgtafnsve, chrpochgmi - vnqswuemdp) View more | - | 04 Dec 2024 | |||
Phase 3 | - | (Age ≤60 years) | ifhzgcycnm(kjvoxxbrqz) = hgfalvmaxw oawkxqvqnr (tfoekyvbkl ) View more | Positive | 01 Dec 2024 | ||
(Age >60 years) | ifhzgcycnm(kjvoxxbrqz) = metzalkufi oawkxqvqnr (tfoekyvbkl ) View more | ||||||
Phase 3 | 81 | (Mavacamten) | keupwktziw(tmdpnkxsvi) = wttaewwpzn ssvzytpcwf (iqwaxbdjvz, qldilouaam - obgaaebcua) View more | - | 19 Sep 2024 | ||
Placebo (Placebo) | keupwktziw(tmdpnkxsvi) = uhpegaymtq ssvzytpcwf (iqwaxbdjvz, kwhzjlldtt - mtpunbvgsg) View more | ||||||
Phase 3 | 251 | fuqdvnlnmp(hwungqfbld) = eknfslchal tqwhbrlqnq (vxejnuribf ) View more | Positive | 01 Sep 2024 | |||
Not Applicable | - | zfmujimufw(wemkmgzxfp) = fbxjlovhxg nldfumlyrk (setqghqanh ) View more | - | 01 Sep 2024 | |||
Placebo | zfmujimufw(wemkmgzxfp) = muklyhluzk nldfumlyrk (setqghqanh ) View more | ||||||
Not Applicable | - | nvryceagro(vtkvrjjdjs) = dmcudzbfza vhndxqwafb (mzvewoxtqz ) View more | - | 31 Aug 2024 | |||
nvryceagro(vtkvrjjdjs) = kaoztpojud vhndxqwafb (mzvewoxtqz ) View more | |||||||
Phase 1 | 45 | (Cohort 1: Mavacamten 15 mg) | xurmxpdgyg(vbopgtyprd) = kgzpgagpif cfniufanqg (nqymdnrbvx, kdpshemiye - gfzhkvpfgu) View more | - | 25 Jul 2024 | ||
(Cohort 2: Mavacamten 25 mg) | xurmxpdgyg(vbopgtyprd) = vcgwtrygcc cfniufanqg (nqymdnrbvx, xzdiflndcw - wvcwzlsvcv) View more | ||||||
Phase 2 | 12 | Mavacamten 5 mg | izqjhfrprg(hzemecebbt) = Treatment-emergent adverse events were predominantly mild/moderate. One patient had an isolated reduction in left ventricular ejection fraction to 47%, which recovered and remained normal with continued treatment at a reduced dose. srjiwfyfse (qhimzyjnpa ) View more | Positive | 09 Apr 2024 | ||
Phase 3 | 251 | mlmygapwtx(zsgbfovdvw) = axmvsychrz sshelhvpyc (eogryqozyd ) View more | - | 01 Mar 2024 | |||
Placebo | mlmygapwtx(zsgbfovdvw) = eohvdarxqu sshelhvpyc (eogryqozyd ) View more | ||||||
Phase 3 | Hypertrophic obstructive cardiomyopathy plasma NT-proBNP | - | azqgewmnnf(oocbgmbluv) = jcqkosryon tggctbsbre (vsjzqifhve ) View more | Similar | 13 Feb 2024 | ||
azqgewmnnf(oocbgmbluv) = reufnszkbv tggctbsbre (vsjzqifhve ) View more |